Funded Biotechnology Startups in San Francisco
Among the 50 most recent biotechnology funding entries in San Francisco, one disclosed round stands far above the rest: Apogee Therapeutics raised $1.3B on…
Among the 50 most recent biotechnology funding entries in San Francisco, one disclosed round stands far above the rest: Apogee Therapeutics raised $1.3B on 2026-05-27, while the next-largest disclosed amounts are $250M (Nurix Therapeutics, 2025-10-22), $200M (Soley Therapeutics, 2026-01-07) and $190M (Osanni Bio, 2026-06-23; Olema Oncology, 2025-11-20). The list also shows a stage and disclosure pattern: “Series Unknown” appears on 25 of 50 rows, and “undisclosed” amounts appear on 4 of 50 rows, leaving comparatively few explicitly labeled early-stage rounds with disclosed sizes.
Temporal clustering is modest but noticeable. The newest entries concentrate in late June 2026 (e.g., Siren Biotechnology on 2026-06-26 for $8M and ALX Oncology on 2026-06-25 for $10M), while disclosed amounts span from a low of $20K (Ossium Health on 2026-04-10) up to the $1.3B outlier; by geography, nearly all companies are listed in San Francisco, with no other city names appearing in the location field. Overall round dates run from 2025-06-18 (two entries: Neurona Therapeutics and Vial) through 2026-06-26 (Siren Biotechnology).
Most recent rounds
50 of 14898 more funded startups
This page shows the 50 most recent rounds (back to Jun 2025). The full 148-company history for this listing is available on a paid plan.
Unlock all 148 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which disclosed round is the outlier, and how far above the rest is it?
Apogee Therapeutics’ $1.3B disclosed round on 2026-05-27 dwarfs the next-largest disclosed amounts: $250M (Nurix Therapeutics, 2025-10-22), $200M (Soley Therapeutics, 2026-01-07), and $190M (Osanni Bio, 2026-06-23; Olema Oncology, 2025-11-20). The $1.3B figure is an order of magnitude above most other disclosed rounds on the page.
How often are round stages explicitly labeled versus left as “Series Unknown,” and what does that imply for filtering?
“Series Unknown” is used on 25 of the 50 rows (for example, Siren Biotechnology on 2026-06-26 for $8M; ALX Oncology on 2026-06-25 for $10M). In addition, 4 of 50 rows list “undisclosed” amounts (e.g., Antogen on 2026-06-09; Manа.bio on 2025-09-14), which reduces the usefulness of amount-based thresholds unless those rows are excluded.
Do funding rounds cluster near the most recent dates?
Yes, the tail end is tight: four disclosed entries land within the last 10 days of June 2026 (Siren Biotechnology $8M on 2026-06-26; ALX Oncology $10M on 2026-06-25; Osanni Bio $190M on 2026-06-23; Kopra Bio $9M on 2026-06-16). Separately, the page includes two rounds dated 2025-06-18 (Neurona Therapeutics $14M and Vial $10M), showing the older end of the displayed window is mid-June 2025.
Is there a clear “low-end” outlier among disclosed amounts?
Ossium Health is the low-end disclosed outlier at $20K on 2026-04-10. That $20K minimum sits well below the smallest other disclosed amounts visible on the page (e.g., UP Oncolytics $80K on 2026-01-07; Revel Pharmaceuticals $80K on 2025-10-09), while several other disclosed rounds cluster in the $1M–$10M band (e.g., Montara Therapeutics $1M on 2026-06-02; ViCardia $700K on 2026-05-21).
Is San Francisco over-represented compared with other geographies in this listing?
San Francisco dominates: every row’s location field lists San Francisco, California, United States (including entries where the city is written as “San Francisco, United States,” such as Hermes Biosciences on 2025-11-23 and Until Labs on 2025-09-23). No other city names appear in the location column, so there is no city-level dispersion to analyze beyond San Francisco-centric concentration.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.